Targeted Molecular Therapy of the PI3K Pathway
نویسندگان
چکیده
منابع مشابه
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sens...
متن کاملMolecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy
Deregulation of the phosphatidylinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling pathway occurs frequently in a wide range of human cancers and is a major driving force in tumorigenesis. Thus, small molecules targeting this pathway are under active development as anticancer therapeutics. Although small-molecule inhibitors of the PI3K-mTOR pathway have shown promising...
متن کاملhedgehog signalling pathway: carcinogenesis and targeted therapy
hedgehog signalling pathway has not only a critical role in cell proliferation, differentiation and tissue polarity at embryonic period but also has a vital role in stem cell proliferation, tissue healing and carcinogenesis. recent research has increased our understanding of this pathway and its relation to other signalling pathways. in addition, a large number of studies confirmed the alterati...
متن کاملSignaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma
In recent years, molecular-targeted agents have been used clinically to treat various malignant tumors. In May 2009, sorafenib (Nexavar ) was approved in Japan for ‘unresectable hepatocellular carcinoma (HCC)’, and was the first molecular-targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase III ra...
متن کاملSignaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma
In recent years, molecular-targeted agents have been used clinically to treat various malignant tumors. In May 2009, sorafenib (Nexavar ) was approved in Japan for ‘unresectable hepatocellular carcinoma (HCC)’, and was the first molecular-targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase III ra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Surgery
سال: 2006
ISSN: 0003-4932
DOI: 10.1097/01.sla.0000220040.66012.a9